Efficacy And Safety Of Ritlecitinib In Asian Patients With Alopecia Areata: A Subgroup Analysis Of The ALLEGRO Phase 2b/3 Trial

This subgroup analysis of the ALLEGRO phase 2b/3 trial evaluated the efficacy and safety of ritlecitinib in 186 Asian patients aged ≥12 years with alopecia areata and ≥50% scalp hair loss. Patients received various doses of ritlecitinib or placebo over 48 weeks. By week 48, 26.5%-55.6% of patients treated with ritlecitinib ≥30 mg achieved a SALT score ≤20, indicating significant hair regrowth. Additionally, 41.9%-71.1% showed improvement in eyebrow assessment, and 40.7%-57.9% in eyelash assessment. Common adverse events included nasopharyngitis and folliculitis, but no serious infections or deaths occurred. Ritlecitinib was effective and safe for this population, aligning with results from the broader study.